CD20×CD3 bispecific T‑cell–engaging antibody that redirects T cells via CD3 to kill CD20+ B cells (IV).
Humanized bispecific antibody that binds CD20 on B cells and CD3 on T cells, crosslinking them to redirect and activate T cells to kill CD20+ B cells.
YES
DIRECT
Bispecific antibody binds CD20 on B cells and CD3 on T cells, crosslinking them to activate T cells and induce perforin/granzyme-mediated killing of CD20+ cells.
CD20×CD3 bispecific T‑cell–engaging antibody that redirects T cells via CD3 to kill CD20+ B cells (IV).
Humanized bispecific antibody that binds CD20 on B cells and CD3 on T cells, crosslinking them to redirect and activate T cells to kill CD20+ B cells.
NO
INDIRECT
Mosunetuzumab binds CD3ε on T cells to recruit and activate them against CD20+ B cells; T cells expressing CD3 are effectors, not targets, and are not directly killed by the drug.
Anti‑CD79b antibody–drug conjugate that delivers the microtubule‑disrupting cytotoxin MMAE to B cells (IV).
Anti-CD79b monoclonal antibody–drug conjugate linked via a protease-cleavable linker to monomethyl auristatin E (MMAE). After binding CD79b on B cells and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of malignant B cells.
YES
DIRECT
The anti-CD79b ADC binds CD79b, is internalized, and releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of the target-expressing cells.
Anti‑CD79b antibody–drug conjugate that delivers the microtubule‑disrupting cytotoxin MMAE to B cells (IV).
Anti-CD79b monoclonal antibody–drug conjugate linked via a protease-cleavable linker to monomethyl auristatin E (MMAE). After binding CD79b on B cells and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of malignant B cells.
NO
INDIRECT
The ADC binds CD79b on B cells, is internalized, and releases MMAE, which inhibits tubulin polymerization (vinca site) to cause mitotic arrest and apoptosis of CD79b+ cells; tubulin expression itself is not the targeting determinant.
Fc‑engineered anti‑CD19 monoclonal antibody that enhances ADCC/ADCP against CD19+ B cells (IV).
Humanized, Fc‑engineered anti‑CD19 monoclonal antibody that binds CD19 on malignant and normal B cells and engages Fcγ receptors on effector cells to enhance antibody‑dependent cellular cytotoxicity (ADCC) and antibody‑dependent cellular phagocytosis (ADCP), leading to depletion of CD19+ B cells.
YES
DIRECT
Binds CD19 on B cells and engages Fcγ receptors on effector cells to trigger ADCC and ADCP, leading to depletion/killing of CD19+ cells.